Approval · Notice of Compliance 9310 · 2008
HUMIRA: Notice of Compliance 9310
Issued January 23, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9310
- Date
- January 23, 2008
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment of adult patients with chronic moderate to severe psoriasis who are candidates for systemic therapy. for patients with chronic moderate plaque psoriasis, humira should be used after phototherapy has been shown to be ineffective or inappropriate
- Therapeutic class
- Biological response modifier
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HUMIRA | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.8ML